immunomic therapeutics crunchbase immunomic therapeutics crunchbase

Immunomic Therapeutics, Inc. is committed to building, developing and retaining a world-class team. UNITE is a groundbreaking approach to vaccine development that has been applied to create vaccine candidates for rabies, yellow fever, dengue fever, hepatitis C and SARS, a relative to the SARS-CoV-2 coronavirus. She succeeds Louise Peltier, Vice President of Regulatory Affairs, who retired on August 31, 2022. This approach could put UNITE at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. ITI is primarily focused on applying the UNITE platform to oncology, where it could potentially have broad applications, including antigen-derived antibodies as biologics. Being able to attract someone with so much collective experience, which has resulted in more than 75 regulatory submissions operating in 125 countries, is a real coup for ITI. Animal Health All. Pay, Holidays and PTO appear to be very good. We provide a professional and challenging work environment . 438 followers 429 connections. Juniper Point At ITI, our success is based in great part on our ability to attract and retain the best, creative, talented, motivated and productive employees throughout our organization. ITI granted Japanese animal health company, ZENOAQ (Nippon Zenyaku Kogyo Co., Ltd, Koriyama, Japan) an exclusive license to develop and commercialize its investigational DNA vaccine for canine atopic dermatitis and other companion animal allergies. Company: Melissa Kemp Immunomic Therapeutics Mkemp@immunomix.com 301-968-3501 Media: Amy Conrad Juniper Point amy@juniper-point.com 858-366-3243 Contacts A $300 million worldwide licensing agreement announced last week between Immunomic Therapeutics and Astellas Pharma to develop treatment for a wide range of allergic diseases, including peanut allergies, is the largest deal ever to come out of Johns Hopkins Technology Ventures, the patent, licensing, and technology . GBM patients white blood cells are removed, matured into dendritic cells and vaccinated against the pp65 viral protein, then returned to the patient. The first ITI oncology clinical program was born as a result of this decision and each subsequent asset in the pipeline represents a natural transition from this original point of entry into oncology. The primary mechanism of action of ITI-1000 is to generate a T cell-mediated immune response against malignant glial cells expressing the CMV pp65 protein. Find your private company bowl on Fishbowl, join the hottest conversation with your colleagues anonymously. ITI-3000 is being tested in a Phase 1, open label, First in Human (FIH) study to evaluate the safety, tolerability, and immunogenicity of 4 mg of ITI-3000 in patients with Merkel polyomavirus-positive Merkel cell carcinoma (MCC). 2020 Immunomic Therapeutics, Inc. All Rights Reserved. Coordinates: 245831.9N 1213154.0E. Active, Closed, Last funding round type (e.g. Immunomic Therapeutics General Information. ITI-1000 is being tested in a randomized, blinded, and placebo-controlled phase 2 study in patients with newly-diagnosed glioblastoma (GBM) that is anticipated to close in 2022. 301-968-3501, ITI Media: Immunomic Therapeutics Announces Open Enrollment for RENEW Clinical Study of CMV RNA-Pulsed Dendritic Cell Vaccine for the. Senior Scientist/Scientist II, Formulation Development. Headquarters Location. Mitchell D.A.,Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the bo dy's natural biochemistry to develop . ITI-3000 is being tested in a Phase 1, open label, First in Human (FIH) study to evaluate the safety, tolerability, and immunogenicity of 4 mg of ITI-3000 in patients with Merkel polyomavirus-positive Merkel cell carcinoma (MCC). Very family oriented. The foundation of a successful company is only as strong as the quality of its employee team. Katie Pearce. We provide a professional and challenging work environment where employees can grow and share in the continued success of the company. View contacts for ImmunoMet Therapeutics to access new leads and connect with decision-makers. ITI-3000 Merkel Cell Carcinoma - pDNA. ROCKVILLE, Md., October 10, 2022--Immunomic Therapeutics, Inc., ("ITI"), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based . IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction. Pancreatic cancer is the fourth-most-common cause of cancer-related mortality in the USA. A privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms | Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the Universal Intracellular Targeted Expression (UNITE) nucleic acid immunotherapy platform. ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (ITI) a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today the close of a $61.3M financing led by HLB Co., LTD, a global pharmaceutical company focused on developing novel cancer drugs. Immunomic Therapeutics, Inc. is committed to building, developing and retaining a world-class team. 917-322-2571, Internet Explorer presents a security risk. The Company has built a pipeline leveraging UNITE with programs in oncology, animal health, infectious disease, and allergy. Seed, Series A, Private Equity), Alternate or previous names for the organization, Whether an Organization is for profit or non-profit, General contact email for the organization. A successful transition from cell to cell-free therapy would provide broad validation to the ITI pDNA pipeline. Prior to her role at BTG, she held senior regulatory positions at a variety of companies specializing in therapeutics for oncology, respiratory, neurology, regenerative medicine, orthopedics and cardiovascular disease including Life Cell Corporation (Allergan), Alphatec Spine, Covidien (Medtronic), Lumenis LTD, and C.R. Clin Cancer Res. If you enjoy the challenge that goes naturally with being part of a high growth company, then a career with Immunomic Therapeutics, Inc. may be just for you. Their LAMP-Vax platform is thought to work by encoding the Lysosomal Associated Membrane Protein, an endogenous protein in . Immunic Therapeutics Investments & Acquisitions (2) Company Name Deal Date Deal Type Deal Size Industry Lead Partner; 00000 0000000: 12-Apr-2019: 0000000000: Drug Discovery: 000000 00: 4SC (immunology portfolio) 28-Sep-2016: For more information, please visit www.immunomix.com. Amy Conrad Great people . Contact Email info@immunomet.com. In addition to TH1 response, we also observe antigen specific antibodies indicative of TH2 response further enhancing the anti-tumor potential of this vaccine.ITI-1001 presents an alternative for patients that missed the treatment window for other therapies or that cannot produce enough cells to start cell therapy manufacturing (~30% of patients). mkemp@immunomix.com Copied ITI-2000 provides an UNITE platform address for HPV+ cancers. In addition, ITI-1001 represents a far more cost-effective approach. ITI-3000 Merkel Cell Carcinoma - pDNA. We have significant capabilities in molecular biology, including nucleic acid vaccine design, immunology, and tumor mouse modeling. The therapy was developed using ITIs proprietary UNITE (UNiversal Intracellular Targeted Expression) platform. Contacts ITI Company Contact: Melissa Kemp mkemp@immunomix.com 301-968-3501 ITI Media Contact: Melody Carey mcarey@rxir.com 917-322-2571 UNITE is currently being employed in Phase II clinical trials as a cancer immunotherapy. Immunomic Therapeutics (ITI) is a clinical stage biotechnology company pioneering investigational technologies that have the potential to alter how immunotherapy is used for cancer, allergies, and animal health. CFO at Immunomic Therapeutics, Inc. Germantown, Maryland, United States. Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal . To ensure the most secure and best overall experience on our website we recommend the latest versions of, Internet Explorer is no longer supported. We are looking for passionate individuals who want to create leading edge technology, thrive in an intellectually stimulating environment, and make a difference in healthcare outcomes. ITI-ID Candidate Multiple infectious diseases. Prior to joining ITI, Ms. Harrison worked as a consultant for various biotechnology companies focused on oncology and infectious disease, leading client interactions with global regulatory authorities regarding product approvals and regulatory planning and implementation. Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the bodys natural biochemistry to develop vaccines that generate broad immune responses. The work and relationships that Louise has fostered over the years position us for successful meetings in the future and I look forward to contributing meaningfully to the companys future regulatory interactions to further advance ITIs development programs utilizing the innovative and proprietary UNITE technology platform.. 917-322-2571, Internet Explorer presents a security risk. Immunomic Therapeutics, Inc. Seed, Series A, Private Equity), Whether an Organization is for profit or non-profit, General contact email for the organization. San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. Company profile for HLB Co. Ltd. including key executives, insider trading, ownership, revenue and average growth rates. This is the Immunomic Therapeutics company profile. Email credentials to careers@immunomix.com. People with disabilities who need a reasonable accommodation to apply or compete for employment with Immunomic Therapeutics may request such accommodation(s) by sending an e-mail to: careers@immunomix.com. Previously, Ms. Harrison served as Senior Vice President, Global Regulatory Affairs and Compliance at BTG International (now Boston Scientific). 301-968-3501 858-366-3243, Internet Explorer presents a security risk. We are looking for passionate individuals who want to create leading edge technology, thrive in an intellectually stimulating environment, and make a difference in healthcare outcomes. UNITE has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy, and autoimmune diseases. A successful transition from cell to cell-free therapy would provide broad validation to the ITI pDNA pipeline. mcarey@rxir.com Leveraging our geographically precise solutions (GPS) platform, we are building a pipeline of tumor-activated cytokine and checkpoint inhibitor immunotherapies to treat cancer. ITI believes that these early clinical studies may provide a proof of concept for UNITE therapy in cancer, and if successful, set the stage for future studies, including combinations in these tumor types and others. Internally, we are able to supply the R&D Team with UNITE products in a timely manner for their ongoing oncology studies. / Oct 13, 2015. Su Y et al., CryJ-LAMP DNA Vaccines for Japanese Red Cedar Allergy Induce Robust Th1-Type Immune Responses in Murine Model. GOLDEN, Colo. December 13, 2022 PharmaJet, a company that engineers precision delivery systems that overcome the challenges of vaccine and pharmaceutical companies, today announced that their partner Immunomic Therapeutics received FDA fast track designation (FTD) for the clinical study of their plasmid DNA vaccine ITI-3000 in patients with Find More Contacts for Immunomic Therapeutics, Diversity Spotlight (US Headquarters Only). Melissa Kemp Total amount raised across all funding rounds, Total number of Crunchbase contacts associated with this organization, Total number of employee profiles an organization has on Crunchbase, Total number of investment firms and individual investors, Total number of organizations similar to the given organization, Descriptive keyword for an Organization (e.g. With HLBs support, we are well-positioned to accelerate our efforts in immuno-oncology, in particular glioblastoma multiforme, and rapidly advance other key candidates in our pipeline, including our most recent initiative into infectious diseases with development of our vaccine candidate for COVID-19.. We provide a professional and challenging work environment where employees can grow and share in the continued success of the company. Pays for all health and welfare insurance premiums 100%. Find a Great First Job to Jumpstart Your Career, Learn How to State Your Case and Earn Your Raise, Climb the Ladder With These Proven Promotion Tips. As a result, we make a significant investment in our employees through our Compensation, Health and Wellness, Retirement and Disability and Career Development programs. Due to the volume of inquiries received, we regret that we cannot contact all applicants personally. Chief Scientific Officer (CSO) Immunomic Therapeutics, Inc. Jun 2019 - Present3 years 9 months. Prior to that, Mr. Stamper held positions of increasing responsibility in various operational areas at Lonza Pharmaceuticals and Biotechnology, AstraZeneca Biologics and Eli Lilly & Company. Melody Carey Jan 2006 - Present17 years 2 months. SaaS, Android, Cloud Computing, Medical Device), Where the organization is headquartered (e.g. ITI-3000 is a plasmid DNA vaccine targeting the large T antigen (LT) of Merkel cell polyomavirus (MCPyV). The company believes this approach may harness the bodys immune system to recognize, attack and destroy tumor cells that express CMV, which is over-expressed in GBM. Contact Email info@immunic.de. Seed, Series A, Private Equity), Whether an Organization is for profit or non-profit, General contact email for the organization. ITI maintains its headquarters in Rockville, Maryland. ROCKVILLE, Md.-- ( BUSINESS WIRE )--Immunomic Therapeutics, Inc., ("ITI") a privately-held clinical-stage biotechnology company pioneering the . Director of Research and Development at Immunomic Therapeutics, Inc. - most recent Rockville, Maryland, United States. Founders Sungwuk Kim. The company held a successful pre-IND meeting earlier this year for ITI-1001 and expects to be able to file an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) by the end of 2020. It is one of the few malignancies for which incidence approximates prevalence, as patients almost always . Companies. Preclinical research data is currently being developed to explore whether the UNITE platform may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response. ITI-1001 represents an off-the-shelf cancer immunotherapy approach that leverages ITIs proprietary UNITE platform to target CMV-associated antigens (pp65, IE-1 & gB) in Newly-Diagnosed Glioblastoma Multiforme (GBM).The primary mechanism of action of ITI-1001 is to enable specific presentation of the antigens via the lysosome mediated pathway in the antigen presenting cells (APC). J Biol Chem. ITI is using the UNITE platform to develop vaccines against various infectious diseases, SARS-CoV-2 (COVID-19) among them. Hum Vaccin Immunother. ITI-2000 HPV+ Tumors. ITI-1000 is a cell therapy powered by ITIs UNITE platform that is currently being evaluated in a Phase II clinical trial (ATTAC-II) in collaboration with researchers at the University of Florida (Dr. Duane Mitchell) and Duke University (Dr. John Sampson). ITI granted Japanese animal health company, ZENOAQ (Nippon Zenyaku Kogyo Co., Ltd, Koriyama, Japan) an exclusive license to develop and commercialize its investigational DNA vaccine for canine atopic dermatitis and other companion animal allergies. AAPL, FB, TWTR), Total amount raised across all funding rounds, Total number of Crunchbase contacts associated with this organization, Total number of employee profiles an organization has on Crunchbase, Total number of investment firms and individual investors, Descriptive keyword for an Organization (e.g. Work Here? ImmunoMet Therapeutics is a biopharmaceutical company that develops and commercializes oncology products for cancer patients. ITI has entered into a significant allergy partnership with Astellas Pharma and has formed several academic collaborations with leading Immuno-oncology researchers at Fred Hutchinson Cancer Research Institute, Johns Hopkins University of Medicine, and Duke University. ITI-1001 represents an off-the-shelf cancer immunotherapy approach that leverages ITIs proprietary UNITE platform to target CMV-associated antigens (pp65, IE-1 & gB) in Newly-Diagnosed Glioblastoma Multiforme (GBM).The primary mechanism of action of ITI-1001 is to enable specific presentation of the antigens via the lysosome mediated pathway in the antigen presenting cells (APC). This employer has not claimed their Employer Profile and is missing out on connecting with our community. Types of diversity represented in an organization, specifically of those who are founding members, currently the CEO, or have check-writing abilities in an investment firm. Book the hotel with real traveler reviews, ratings and latest pictures of Chinatrust Executive House Hsin-Tien. Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company revolutionizing the study of the Lysosomal Associated Membrane . mkemp@immunomix.com 301-968-3501 Cytokines secreted by CD4+ T cells, such as IFN, can also exert desirable effects on the tumor microenvironment. 2015 Mar 19;519(7543):366-9. Nature. All content is posted anonymously by employees working at Immunomic Therapeutics. 2017 Apr 15;23(8):1898-1909. 28 Employees . Description. Immunic is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. Individuals who thrive in our environment are team-oriented, self-motivated, creative, and persistent. ITI maintains its headquarters in Rockville, Maryland. The financing will also enable Immunomic to expand its team and infrastructure to support the future growth of the company. Immunomic Therapeutics' continued investment in Process Development provides value in several ways. This is the Immunomic Therapeutics company profile. ITI-1001 GBM - pDNA. MiNA Therapeutics Limited Translation & Innovation Hub 84 Wood Lane London W12 0BZ United Kingdom. These factors are currently under intense focus in the cancer immunotherapy landscape. ROCKVILLE, Md.-- ( BUSINESS WIRE )--Immunomic Therapeutics, Inc., ("ITI"), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based . For more information, please visit www.immunomix.com. Join to connect Immunomic Therapeutics, Inc. Mount Saint Mary's College. 2017 Aug;47:85-92. Concurrent with the financing, five (5) members from HLB Co., LTD will be joining the Immunomic Therapeutics Board of Directors. pipeline of metabolic regulators preferentially targeting the cellular metabolism of drug-resistant cancer subpopulations and immuno-suppressors of anti-cancer effector T cells. We know that there are multiple aspects that inform our platform's success. ImmunoMet Therapeutics is a development-stage biopharmaceutical company focused on the development and commercialization of novel oncology products . amy@juniper-point.com Curr Opin Immunol. 2020 Immunomic Therapeutics, Inc. All Rights Reserved. To ensure the most secure and best overall experience on our website we recommend the latest versions of, Internet Explorer is no longer supported. The antigens mainly elicits TH1 response leading to cytokine release, development of cytotoxic CD8 T cells and memory CD4 T cells. Immunomic Therapeutics, Inc. (ITI) is a privately-held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the bodys natural biochemistry to develop vaccines that generate broad immune responses. See Immunomic Therapeutics funding rounds, investors, investments, exits and more. For consideration, please send your company information, a copy of your standard search agreement, and references to: careers@immunomix.com. ITI is using the UNITE platform to develop vaccines against various infectious diseases, SARS-CoV-2 (COVID-19) among them. ITI-2000 provides an UNITE platform address for HPV+ cancers. IMU-935, a selective inverse agonist of the transcription factor RORt, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barr syndrome. Stemming from our UNITE Platform, Immunomic Therapeutics has developed a robust and deep pipeline focused on immunotherapeutics with an emphasis in treating and preventing many oncology indications by leveraging specific characteristics of a type of antigen. ITI maintains its headquarters in Rockville, Maryland. For more information, please visit www.immunomix.com. Today, Brian Stamper, VP, Immunomic Therapeutics, will participate at #MTC's Annapolis Day 2023. Immunomic Therapeutics' nucleic acid vaccines have the . MiNA Therapeutics Limited Translation & Innovation Hub 84 Wood Lane London W12 0BZ United Kingdom. Clin Cancer Res 2020;26:5297303, Batich K.A.,Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination. mcarey@rxir.com -Proceeds to support acceleration of Phase II clinical trial for GBM, advancement of pipeline, including development of COVID-19 vaccine candidate and expansion of opportunities for its UNITE nucleic acid platform-. As a result, a robust T cell response by both CD4+ and CD8+ T cells is expected to drive antitumor activity of this product. The therapy was developed using ITIs proprietary UNITE (UNiversal Intracellular Targeted Expression) platform. Where the organization is headquartered (e.g. The oncogenes E6 and E7 in both HPV 16 and HPV 18 strains are well proven to be immunogenic, providing the support to develop this product.ITI-2000, delivered by needle and syringe as a self-amplifying construct, will be indicated for HPV-positive cancers. Of special note are the following publications: To browse the literature, please see the curated list at PubMed. Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal . Glassdoor gives you an inside look at what it's like to work at Immunomic Therapeutics, including salaries, reviews, office photos, and more. To ensure the most secure and best overall experience on our website, we recommend the latest versions of. In addition, ITI-1001 represents a far more cost-effective approach. 2020 Immunomic Therapeutics, Inc. All Rights Reserved. I would also like to take the opportunity to sincerely thank Louise Peltier for her leadership over the last seven years and wish her well in her retirement., I am both honored and excited to be joining Immunomic Therapeutics at such a critical point in its growth cycle, said Ms. Harrison. Should we find that your skills and experience match our position needs, a Immunomic Therapeutics, Inc. representative will contact you to discuss the opportunity. November 30, 2021, 7:01 PM UTC. Please include the Job Code in the subject line and attach a cover letter and salary requirement along with a current resume to complete your candidacy submission for each position in which you are interested. The New Taipei Municipal Hsin Tien Senior High School ( Chinese: ) is a senior high school in Xindian District, New Taipei, Taiwan which was founded in 1992. ITIs investigational UNITE platform, or UNiversal Intracellular Targeted Expression, works by fusing pathogenic antigens with the Lysosomal Associated Membrane Protein, an endogenous protein in humans, for immune processing. Find More Contacts for ImmunoMet Therapeutics, Edit Lists Featuring This Company Section, Dr. Revati Shreeniwas Joins ImmunoMet Therapeutics as Chief Medical Officer, ImmunoMet Therapeutics Appoints Vincent ONeill Chief Medical Officer, Health Care Companies With Less Than $1M in Revenue (Top 10K), Pharmaceutical Companies With Fewer Than 1000 Employees (Top 10K), Southern US Companies With Less Than $50M in Revenue (Top 10K). ITI-1000 is currently being investigated in a Phase 2 ATTAC-II trial at UF and Duke. Find all information and best deals of Chinatrust Executive House Hsin-Tien, New Taipei City on Trip.com! Immunomic Therapeutics is a development stage biotechnology company that develops lysosomal associated membrane protein-based vaccines. What is health insurance like at Immunomic Therapeutics. We are a patient advocacy company that understands that patient enrollment in clinical trials is critical to advancements in medicine and patient treatment. With more than 6 years of experience in the field of cancer metabolism and immunometabolism, ImmunoMet has developed a comprehensive. Those studies had enrolled all comers, and Bristol restricted Checkpoint-548's enrolment to patients carrying the MGMT methylation biomarker in . But a few things must happen first. Active, Closed, Last funding round type (e.g. The oncogenes E6 and E7 in both HPV 16 and HPV 18 strains are well proven to be immunogenic, providing the support to develop this product.ITI-2000, delivered by needle and syringe as a self-amplifying construct, will be indicated for HPV-positive cancers. Company profile page for Immunomic Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information On behalf of the management team, I am pleased to welcome Ms. Harrison to ITI. Rockville, Maryland, 20850, United States. Bard (Becton, Dickinson and Company). To ensure the most secure and best overall experience on our website we recommend the latest versions of, Internet Explorer is no longer supported. It is interesting to note that the emerging market of brain tumor includes budding gene therapies, i.e., Ofranergene obadenovec (VBL Therapeutics) and Ad-RTS-hIL-12 in combination with Veledimex . Su Y et al., Safety and long-term immunological effects of CryJ2-LAMP plasmid vaccine in Japanese red cedar atopic subjects: A phase I study. Active, Closed, Last funding round type (e.g. Innovative Cellular Therapeutics (ICT) is a clinical-stage, VC-backed cell therapy company based in Rockville, MD. Brian joins the company with over 20 years of experience in cell therapy operations, pharmaceutical manufacturing, and process engineering. All content is posted anonymously by employees working at Immunomic Therapeutics. The majority of Merkel cell carcinomas (MCC), a rare but aggressive form of skin cancer, are associated with MCPyV infection, making LT an attractive target for this cancer vaccine. Be sure to include your name, the Job Code of the job you are interested in, and the accommodation you are seeking. Report this profile . Our goal is to overcome the limitations of current immuno-oncology therapies by . ITI-1000 is a dendritic cell therapy comprised of autologous dendritic cells (DCs) loaded with messenger ribonucleic acid (mRNA) encoding the human Lysosomal Associated Membrane Protein (hLAMP) gene fused in frame to a human Cytomegalovirus (hCMV) matrix protein, pp65 gene (hLAMP:pp65) and subsequently administered with Granulocyte-macrophage colony-stimulating factor (GM-CSF) and Tetanus/diphtheria (Td) toxoid which serve as adjuvants. Proceeds from the financing will support the acceleration of ITI's Phase II clinical trial of ITI-1000 for the treatment of glioblastoma multiforme (GBM), advance its emerging pipeline, and expand upon the current applications of its UNITE platform. The company believes this approach may harness the bodys immune system to recognize, attack and destroy tumor cells that express CMV, which is over-expressed in GBM. Immunomic Therapeutics, Inc. (ITI) is a privately-held, clinical stage biotechnology company pioneering the development of vaccines through its investigational proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the body's natural biochemistry to develop vaccines that have the . Over 100 studies have been published on LAMP, ranging from those focused on the fundamental biology of lysosomal associated membrane protein to the immunobiology of novel vaccine candidates. Immunomic Therapeutics, Inc. Biotechnology Research Rockville, MD 2,335 followers A privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms Arruda L.B., et al., Dendritic Cell-Lysosomal-Associated Membrane Protein (LAMP) and LAMP-1-HIV-1 Gag Chimeras Have Distinct Cellular Trafficking Pathways and Prime T and B Cell Responses to a Diverse Repertoire of Epitopes.